Stock listing
Frankfurt:E2Z Almirall SA Aktie
German listing (Frankfurt) of Almirall SA · home listing BME:ALM
Follow Almirall SA into a list and get an email when it puts out news.
Share price · FWB:E2Z
€10.06 EUR -0.26 (-2.5%)
Close on Nov 20, 2026
- Day range
- €10.06 – €10.06 EURNov 20, 2026
- Market cap
- €2.19B EURAt the close on Nov 20, 2026 · price × 217.6M shares outstanding
- 52-week range
- €9.81 – €13.76 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3,161 EURMedian day 0 shares · 32 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| BME:ALM · Home | €10.26 EUR | -0.06 (-0.6%) | 114,854 | €10.16 | €10.30 | €10.10 | €10.32 | Close on Nov 20, 2026 |
| OTC:LBTSF | $15.35 USD | 0.00 (0.0%) | — | $15.35 | $15.35 | $15.35 | $15.35 | Close on Nov 6, 2026 |
| Frankfurt:E2Z | €10.06 EUR | -0.26 (-2.5%) | — | €10.06 | €10.06 | €10.06 | €10.32 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:E2Z · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €11.05 | +0.043 | +0.4% | €11.05 | €11.05 | €11.05 | 0 | |
| €11.01 | +0.202 | +1.9% | €11.01 | €11.01 | €11.01 | 1,038 | |
| €10.81 | +0.279 | +2.7% | €10.81 | €10.81 | €10.81 | 1,038 | |
| €10.53 | +0.047 | +0.4% | €10.53 | €10.53 | €10.53 | 0 | |
| €10.48 | +0.002 | 0.0% | €10.48 | €10.48 | €10.48 | 10 | |
| €10.48 | +0.122 | +1.2% | €10.40 | €10.67 | €10.39 | 10 | |
| €10.36 | -0.076 | -0.7% | €10.36 | €10.36 | €10.36 | 32 | |
| €10.43 | +0.043 | +0.4% | €10.43 | €10.43 | €10.43 | 96 | |
| €10.39 | +0.031 | +0.3% | €10.32 | €10.39 | €10.24 | 145 | |
| €10.36 | +0.114 | +1.1% | €10.36 | €10.36 | €10.30 | 145 | |
| €10.25 | -0.023 | -0.2% | €10.25 | €10.25 | €10.25 | 7,302 | |
| €10.27 | -0.079 | -0.8% | €10.27 | €10.27 | €10.27 | 0 | |
| €10.35 | +0.542 | +5.5% | €10.35 | €10.35 | €10.35 | 0 | |
| €9.805 | -0.164 | -1.6% | €9.805 | €9.805 | €9.805 | 0 | |
| €9.969 | -0.09 | -0.9% | €10.04 | €10.09 | €9.857 | 0 | |
| €10.06 | +0.01 | +0.1% | €10.06 | €10.06 | €10.06 | 0 | |
| €10.05 | +0.196 | +2.0% | €10.05 | €10.05 | €10.05 | 0 | |
| €9.853 | -0.027 | -0.3% | €9.853 | €9.853 | €9.853 | 0 | |
| €9.88 | -0.106 | -1.1% | €9.88 | €9.88 | €9.88 | 0 | |
| €9.986 | -0.049 | -0.5% | €10.00 | €10.00 | €9.966 | 20 | |
| €10.04 | -0.139 | -1.4% | €10.04 | €10.04 | €10.04 | 240 | |
| €10.17 | +0.091 | +0.9% | €10.17 | €10.17 | €10.17 | 132 | |
| €10.08 | -0.008 | -0.1% | €10.08 | €10.08 | €10.08 | 0 | |
| €10.09 | -0.111 | -1.1% | €10.09 | €10.09 | €10.09 | 0 | |
| €10.20 | +0.01 | +0.1% | €10.20 | €10.20 | €10.20 | 0 | |
| €10.19 | -0.297 | -2.8% | €10.18 | €10.21 | €10.17 | 1,000 | |
| €10.49 | +0.153 | +1.5% | €10.49 | €10.49 | €10.49 | 0 | |
| €10.34 | -0.083 | -0.8% | €10.34 | €10.34 | €10.34 | 0 | |
| €10.42 | -0.079 | -0.8% | €10.42 | €10.42 | €10.42 | 0 | |
| €10.50 | -0.003 | 0.0% | €10.54 | €10.55 | €10.45 | 1 | |
| €10.50 | +0.193 | +1.9% | €10.50 | €10.50 | €10.50 | 450 | |
| €10.31 | -0.28 | -2.6% | €10.31 | €10.31 | €10.31 | 0 | |
| €10.59 | +0.033 | +0.3% | €10.59 | €10.59 | €10.59 | 0 | |
| €10.56 | +0.056 | +0.5% | €10.56 | €10.56 | €10.56 | 7 | |
| €10.50 | +0.017 | +0.2% | €10.52 | €10.54 | €10.34 | 500 | |
| €10.48 | -0.209 | -2.0% | €10.48 | €10.48 | €10.48 | 216 | |
| €10.69 | +0.189 | +1.8% | €10.69 | €10.69 | €10.69 | 0 | |
| €10.50 | +0.007 | +0.1% | €10.50 | €10.50 | €10.50 | 0 | |
| €10.50 | +0.207 | +2.0% | €10.35 | €10.66 | €10.28 | 1,010 | |
| €10.29 | +0.142 | +1.4% | €10.08 | €10.32 | €10.07 | 1,000 | |
| €10.15 | +0.078 | +0.8% | €10.15 | €10.15 | €10.15 | 6 | |
| €10.07 | -0.184 | -1.8% | €10.07 | €10.07 | €10.07 | 0 | |
| €10.25 | -0.033 | -0.3% | €10.25 | €10.25 | €10.25 | 0 | |
| €10.29 | -0.117 | -1.1% | €10.29 | €10.29 | €10.29 | 0 | |
| €10.40 | -0.007 | -0.1% | €10.40 | €10.40 | €10.40 | 11 | |
| €10.41 | -0.026 | -0.2% | €10.41 | €10.41 | €10.33 | 8 | |
| €10.44 | -0.006 | -0.1% | €10.44 | €10.44 | €10.44 | 0 | |
| €10.44 | +0.158 | +1.5% | €10.44 | €10.44 | €10.44 | 0 | |
| €10.28 | -0.016 | -0.2% | €10.28 | €10.28 | €10.28 | 0 | |
| €10.30 | -0.099 | -1.0% | €10.30 | €10.30 | €10.30 | 0 | |
| €10.40 | -0.061 | -0.6% | €10.40 | €10.40 | €10.40 | 6 | |
| €10.46 | +0.195 | +1.9% | €10.46 | €10.46 | €10.46 | 0 | |
| €10.26 | +0.068 | +0.7% | €10.26 | €10.26 | €10.26 | 0 | |
| €10.20 | -0.253 | -2.4% | €10.20 | €10.20 | €10.20 | 0 | |
| €10.45 | +0.159 | +1.5% | €10.45 | €10.45 | €10.45 | 0 | |
| €10.29 | -0.043 | -0.4% | €10.29 | €10.29 | €10.29 | 2,966 | |
| €10.33 | -0.189 | -1.8% | €10.33 | €10.33 | €10.33 | 0 |
- Ticker
- Frankfurt:E2Z
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Almirall 9M 2026 Results
Latest earnings call · Jul 24, 2026
Almirall (Madrid:ALM) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Jul 24, 2026
H1 2026 Earnings Presentation
Earnings · 30 slides
Latest news
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab
Oct 1, 2026
Closed €10.49 (+1.5%) on Oct 1, 2026
Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026
Sep 30, 2026
Closed €10.34 (-0.8%) on Sep 30, 2026
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology
Aug 10, 2026
Closed €10.80 (-0.7%) on Aug 10, 2026
Almirall H1 2026 Results
Jul 24, 2026
Closed €10.99 (+1.3%) on Jul 24, 2026
Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older
Jul 20, 2026
Closed €10.62 (+1.6%) on Jul 20, 2026
Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business
May 11, 2026
Closed €12.08 (+0.5%) on May 11, 2026
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
Apr 13, 2026
Closed €12.84 (+1.9%) on Apr 13, 2026
Almirall enters collaboration with Huaota for the development of a novel monoclonal antibody in medical dermatology
Mar 30, 2026
Closed €12.15 (+2.0%) on Mar 31, 2026
Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
Mar 27, 2026
Closed €11.85 (+2.7%) on Mar 27, 2026
Almirall SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 34 in all · newest Nov 9, 2026 · oldest 2024
- Calls
- 14 calls with a replay · 14 with a transcript · latest Jul 24, 2026
- Decks
- 39 decks · latest Jul 24, 2026
Where Almirall SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| BME:ALM · Home listing | Madrid | Spain | EUR |
| gettex:E2Z | gettex | Germany | EUR |
| LS Exchange:A0MU8Y | LS Exchange | Germany | EUR |
| OTC:ALMRY | OTC | United States | USD |
| Lang & Schwarz:A0MU8Y | Lang & Schwarz | Germany | EUR |
| Aquis:ALME | Aquis | United Kingdom | EUR |
| LSIN:0O9B | LSIN | United Kingdom | EUR |
| OTC:LBTSF | OTC | United States | USD |
| Aquis:ALME | Aquis | United Kingdom | EUR |
| Tradegate:E2Z | Tradegate | Germany | EUR |
| Frankfurt:E2Z · This page | Frankfurt | Germany | EUR |
| Frankfurt:E2Z0 | Frankfurt | Germany | EUR |
| VIE:ALM | Vienna | Austria | EUR |
| Dusseldorf:E2Z | Dusseldorf | Germany | EUR |
| Hamburg:E2Z | Hamburg | Germany | EUR |
| Munich:E2Z | Munich | Germany | EUR |
| Stuttgart:E2Z | Stuttgart | Germany | EUR |
| Turquoise:ALME | Turquoise | United Kingdom | EUR |
Valuation
EV/sales 1.6× against a median of 18.4×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €2.24B EUR
- P/E
- 31.1×
- EV/sales
- 1.6×
- EV/EBITDA
- 7.3×
- Price/book
- 1.5×
- Gross margin
- 74.0%
- Operating margin
- 8.5%
- Net margin
- 5.1%
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Almirall SA · BME:ALM | US$2.45B | US$2.46B | 31.1× | 1.6× | 7.3× | 1.5× | 5.1% | 0.2× | n/a |
| HLB Co., Ltd. · KRX:028300 | US$2.69B | US$2.69B | n/a | 36.9× | n/a | 10.4× | −219.1% | 0.2× | n/a |
| Celcuity Inc. · NASDAQ:CELC | US$2.62B | US$1.98B | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Zai Lab Ltd. · HKEX:9688 | US$2.60B | US$2.04B | n/a | 4.6× | n/a | 4.6× | −44.9% | 0.0× | n/a |
| Xencor, Inc. · NASDAQ:XNCR | US$2.50B | US$2.16B | n/a | 10.8× | n/a | 4.5× | −58.8% | 0.1× | 1.21 |
| IDEAYA Biosciences, Inc. · NASDAQ:IDYA | US$2.47B | US$1.66B | n/a | 45.5× | n/a | 2.3× | n/a | 0.0× | 0.96 |
| MBX Biosciences, Inc. · NASDAQ:MBX | US$2.46B | US$1.98B | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 1.30 |
| Keymed Biosciences, Inc. · HKEX:2162 | US$2.43B | US$2.04B | n/a | 19.6× | n/a | 4.0× | −73.0% | 0.2× | n/a |
| InSilico Medicine Cayman TopCo · HKEX:3696 | US$2.29B | US$1.70B | n/a | 30.3× | n/a | 4.2× | −626.5% | 0.0× | n/a |
| SK bioscience Co.,Ltd. · KRX:302440 | US$2.26B | US$2.03B | n/a | 4.1× | n/a | 1.7× | −12.8% | 0.3× | n/a |
| Arcus Biosciences, Inc. · NYSE:RCUS | US$2.25B | US$1.72B | n/a | 17.2× | n/a | 6.3× | −453.0% | 0.3× | 1.37 |
| Median of the others | US$2.47B | US$2.01B | 18.4× | 4.5× | −73.0% | 0.1× | 1.21 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.23 EUR · Analysts' mean
- EPS, year to Dec 2026
- 0.40 · 5 analysts
- Revenue, year to Dec 2026
- 1.23B · 10 analysts
Team and board
| Officer | Role |
|---|---|
| Jon U. Garay Alonso | CFO |
Events
- Next results
- Feb 22, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Almirall (Madrid:ALM) Q2 2026 Earnings Call | Fri, Jul 24, 2026 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q1 2026 Earnings Call | Mon, May 11, 2026 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q4 2025 Earnings Call | Mon, Feb 23, 2026 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q3 2025 Earnings Call | Tue, Nov 11, 2025 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q2 2025 Earnings Call | Fri, Jul 25, 2025 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q1 2025 Earnings Call | Mon, May 12, 2025 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q4 2024 Earnings Call | Mon, Feb 24, 2025 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q3 2024 Earnings Call | Mon, Nov 11, 2024 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q2 2024 Earnings Call | Mon, Jul 22, 2024 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q1 2024 Earnings Call | Mon, May 13, 2024 · 4:00 AM ET | Replay |
All 14 calls
| Call | When | Status |
|---|---|---|
| Almirall (Madrid:ALM) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q2 2023 Earnings Call | Mon, Jul 24, 2023 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q1 2023 Earnings Call | Mon, May 08, 2023 · 4:00 AM ET | Replay |
| Almirall (Madrid:ALM) Q4 2023 Earnings Call | Sun, Feb 19, 2023 · 4:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 9, 2026 · After close | +0.6% |
| Q2 2026 | Jul 24, 2026 · After close | +0.5% |
| Q1 2026 | May 11, 2026 · After close | 0.0% |
| Q1 2025 | May 12, 2025 | +6.3% |
| Q4 2024 | Feb 24, 2025 | +7.0% |
| Q3 2024 | Nov 11, 2024 · Before open | −4.0% |
| Q2 2024 | Jul 22, 2024 · Before open | +2.7% |
| Q1 2024 | May 13, 2024 · Before open | +1.4% |
| Q4 2023 | Feb 19, 2024 · Before open | +5.6% |
| Q3 2023 | Nov 9, 2023 · Before open | −1.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 24, 2023 · Before open | +0.3% |
| Q1 2023 | May 8, 2023 · Before open | +0.2% |
| Q3 2022 | Nov 9, 2022 · After close | +0.7% |
| Q2 2022 | Jul 25, 2022 · Before open | −2.9% |
| Q1 2022 | May 8, 2022 · After close | −11.4% |
| Q4 2021 | Feb 21, 2022 | +7.2% |
| Q3 2021 | Nov 14, 2021 · After close | −11.1% |
| Quarter to Jun 30, 2021 | Jul 26, 2021 · Before open | −11.6% |
| Quarter to Mar 31, 2021 | May 10, 2021 · Before open | +8.4% |
| Quarter to Dec 31, 2020 | Feb 22, 2021 · Before open | −1.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 30 slides | Jul 24, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 29 slides | May 11, 2026 |
| FY 2025 Earnings Presentation | Earnings | 34 slides | Feb 23, 2026 |
| Q1 2025 Earnings Presentation | Earnings | 28 slides | May 12, 2025 |
| FY2024 Earnings Presentation | Earnings | 41 slides | Feb 24, 2025 |
| H1 2024 Earnings Presentation | Earnings | 33 slides | Jul 22, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 31 slides | May 13, 2024 |
| FY2023 Earnings Presentation | Earnings | 42 slides | Feb 19, 2024 |
| FY2022 Earnings Presentation | Earnings | 39 slides | Feb 20, 2023 |
| Q1 2022 Earnings Presentation | Earnings | 45 slides | May 9, 2022 |
All 39 decks
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.11B | 985.7M | 894.5M | 863.2M | 827.2M | 1.61B | 855.3M | 756.9M | 639.4M | 764.4M |
| Cost of revenue | 651.4M | 218.0M | 317.4M | 182.5M | 171.6M | 173.4M | 192.5M | 162.6M | 173.0M | 162.8M |
| Gross profit | 456.6M | 767.7M | 577.1M | 680.8M | 655.6M | 1.44B | 662.9M | 594.3M | 466.4M | 601.6M |
| Research and development | 138.1M | 79.0M | 66.9M | 64.3M | 42.0M | 44.1M | 47.7M | 87.6M | 87.9M | 98.3M |
| Selling, general and administrative | 33.3M | 31.3M | 30.4M | 28.7M | 28.4M | 31.5M | 35.5M | 43.4M | 84.1M | 89.8M |
| Operating income | 73.1M | 36.1M | -5.26M | 46.9M | 5.75M | 92.3M | 149.9M | 87.0M | -310.0M | 111.6M |
| Depreciation and amortization | 151.2M | 139.1M | 124.3M | 120.6M | 119.9M | 123.1M | 129.4M | 90.2M | 103.7M | 100.3M |
| EBITDA | 224.2M | 175.2M | 119.1M | 167.5M | 125.7M | 215.4M | 279.3M | 177.2M | -206.4M | 211.9M |
| Interest expense | 16.9M | 15.7M | 14.6M | 12.8M | 20.6M | 11.0M | 14.8M | 7.94M | 22.8M | 20.1M |
| Income before tax | 74.4M | 26.5M | -17.2M | 31.0M | -9.09M | 79.2M | 128.3M | 75.0M | -321.1M | 92.6M |
| Income tax | 28.3M | 16.4M | 21.3M | 26.7M | 31.8M | 4.96M | 22.4M | -2.70M | -17.1M | 17.2M |
| Net income | 46.2M | 10.1M | -38.5M | 4.28M | -40.9M | 74.3M | 105.9M | 77.7M | -304.0M | 75.5M |
| Earnings per share, basic | 0.22 | 0.05 | -0.18 | 0.02 | -0.23 | 0.39 | 0.56 | 0.41 | -1.75 | 0.44 |
| Earnings per share, diluted | 0.22 | 0.05 | -0.18 | 0.02 | -0.23 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 337.8M | 377.1M | 388.0M | 248.8M | 207.4M | 159.6M | 117.2M | 85.2M | 211.5M | 249.5M |
| Short-term investments | 1.05M | 201.0K | 136.0K | 443.0K | 899.0K | 6.03M | 82.0K | 1.08M | 68.7M | 217.2M |
| Receivables | 158.5M | 151.4M | 131.5M | 138.3M | 127.7M | 87.7M | 243.0M | 231.7M | 147.4M | 176.2M |
| Inventory | 178.1M | 171.8M | 167.5M | 130.1M | 118.6M | 130.1M | 106.0M | 92.2M | 82.8M | 91.0M |
| Current assets | 714.0M | 741.1M | 718.7M | 552.7M | 499.3M | 489.8M | 476.6M | 414.4M | 515.4M | 738.6M |
| Property, plant and equipment | 168.9M | 153.8M | 141.3M | 124.1M | 117.4M | 123.0M | 121.8M | 110.5M | 119.7M | 127.0M |
| Goodwill | 316.0M | 316.0M | 316.0M | 316.0M | 316.0M | 316.0M | 316.0M | 316.0M | 341.8M | 432.8M |
| Total assets | 2.34B | 2.40B | 2.37B | 2.15B | 2.14B | 2.29B | 2.44B | 2.39B | 2.18B | 2.82B |
| Accounts payable | 193.9M | 186.5M | 181.4M | 184.3M | 177.8M | 162.1M | 222.5M | 191.0M | 140.6M | 237.3M |
| Current liabilities | 350.6M | 353.4M | 351.1M | 274.6M | 281.0M | 474.6M | 316.5M | 244.1M | 348.4M | 371.6M |
| Long-term debt | 290.3M | 353.1M | 348.4M | 353.2M | 363.5M | 230.0M | 270.2M | 532.1M | 262.6M | 331.1M |
| Total debt | 342.9M | 408.8M | 403.2M | 403.9M | 396.1M | 497.0M | 502.6M | 535.4M | 264.5M | 338.6M |
| Total liabilities | 829.7M | 908.3M | 911.6M | 829.0M | 855.7M | 988.1M | 1.16B | 1.20B | 1.04B | 1.30B |
| Shareholders' equity | 1.49B | 1.49B | 1.46B | 1.32B | 1.29B | 1.30B | 1.28B | 1.19B | 1.13B | 1.52B |
| Shares outstanding | 214.8M | 211.4M | 197.0M | 180.8M | 178.9M | 188.9M | 187.9M | 187.9M | 173.4M | 173.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 174.5M | 160.8M | 93.5M | 155.1M | 233.9M | 164.8M | 276.1M | 143.2M | 6.09M | 105.1M |
| Capital spending | -34.9M | -29.8M | -33.5M | -23.0M | -18.8M | -76.5M | -135.1M | -598.5M | -68.8M | -76.6M |
| Free cash flow | 139.5M | 130.9M | 60.0M | 132.1M | 215.0M | 88.2M | 141.1M | -455.3M | -62.7M | 28.4M |
| Cash from investing | -126.7M | -140.0M | -122.6M | -68.5M | -57.3M | -23.5M | -144.6M | -608.0M | -67.2M | -457.2M |
| Cash from financing | -87.1M | -31.6M | 168.2M | -45.1M | -134.9M | -40.9M | -100.5M | 270.8M | -125.4M | -49.1M |
| Dividends paid | -26.2M | -3.29M | -2.59M | -12.4M | -11.7M | -2.13M | -24.1M | -22.7M | -33.0M | -33.0M |
| Share buybacks | -1.31M | -539.0K | -157.0K | -46.0K | -596.0K | -487.0K | -1.77M | |||
| Change in cash | -39.3M | -10.9M | 139.1M | 41.4M | 41.7M | 48.4M | 31.0M | -194.0M | -186.5M | -401.3M |
Cap table
Built by 6ix from Almirall SA’s releases
- Common shares
- 217,605,462
- Fully diluted
- 217,605,462
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 217,605,462 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 217,605,462 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Gu | CFO · Feb 10, 2026 – Nov 5, 2026 · Past |
| Jon U. Garay Alonso | CFO · Since at least Mar 6, 2025 |
Log in to ask 6ix AI your own questions about Almirall SA.